Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Product Highlight - Erleada

26 Jun 2020
For your patients with high risk# nmCRPC
Prescribing Erleada may help them delay metastasis and/or live longer1

Erleada is a potent androgen receptor (AR) inhibitor indicated for the treatment of patients with high risk non-metastasis castration-resistant prostate cancer (nmCRPC)

In the SPARTAN Study1:
  • Erleada +ADT improved median Metastasis Free Survival after (MFS) for more than 2 years (24.3 months) compared with placebo + ADT (40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)1
  • Erleada + ADT when compared to ADT alone showed: 25% risk reduction in death and 51% risk reduction of PFS21
  • Erleada + ADT demonstrated statistically significant improvement in time to symptomatic progression, time to metastasis, PFS, time to PSA progression and PSA decline.1
  • Erleada provides convenience with once daily oral dosing.2
  • Erleada +ADT was well tolerated and maintained HRQoL of nmCRPC patients.1

#PSA doubling period ≤10 months; PFS: Progression Free Survival; ADT: Androgen deprivation therapy; PSA: Prostate specific antigen; HRQoL: Health-related Quality of Life


References:
1. Smith MR, et al. N Engl J Med. 2018;378(15):1408–18.
2. ERLEADA (apalutamide) approved prescribing information MalaysiaE uSmPC v Jan 2019


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.